{"id":"regadenoson-peripheral-peripheral","safety":{"commonSideEffects":[{"rate":"26-46%","effect":"Flushing"},{"rate":"28-35%","effect":"Dyspnea"},{"rate":"15-25%","effect":"Chest discomfort"},{"rate":"10-15%","effect":"Headache"},{"rate":"5-10%","effect":"Palpitations"},{"rate":"5-8%","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL5315108","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Regadenoson selectively binds to adenosine A2A receptors on vascular smooth muscle cells in coronary and peripheral arteries, causing vasodilation and increased blood flow. This mimics the hemodynamic effects of exercise stress without the physical exertion, allowing assessment of coronary perfusion and cardiac function during imaging studies. The peripheral vasodilation effect is utilized in peripheral vascular applications to improve blood flow in compromised vascular beds.","oneSentence":"Regadenoson is an adenosine A2A receptor agonist that causes peripheral vasodilation to increase blood flow, used as a pharmacologic stress agent for cardiac imaging.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:42.464Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise"},{"name":"Peripheral vascular insufficiency and claudication (investigational)"}]},"trialDetails":[{"nctId":"NCT03331380","phase":"NA","title":"Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-01-05","conditions":"CAD","enrollment":2950},{"nctId":"NCT03102125","phase":"PHASE4","title":"Allograft Dysfunction in Heart Transplant","status":"RECRUITING","sponsor":"Paul Kim","startDate":"2019-10-01","conditions":"Heart Transplant Failure and Rejection","enrollment":376},{"nctId":"NCT03354273","phase":"PHASE3","title":"An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-06-05","conditions":"Coronary Artery Disease (CAD)","enrollment":730},{"nctId":"NCT01949844","phase":"NA","title":"Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies","status":"COMPLETED","sponsor":"Daniel S. Berman","startDate":"2014-05-16","conditions":"Coronary Artery Disease, CAD","enrollment":44},{"nctId":"NCT01482169","phase":"NA","title":"Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)","status":"COMPLETED","sponsor":"Ochsner Health System","startDate":"2012-03","conditions":"Coronary Artery Disease","enrollment":48},{"nctId":"NCT01809743","phase":"PHASE3","title":"Regadenoson and Adenosine","status":"COMPLETED","sponsor":"Lokien van Nunen","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Regadenoson peripheral - peripheral","genericName":"Regadenoson peripheral - peripheral","companyName":"Lokien van Nunen","companyId":"lokien-van-nunen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regadenoson is an adenosine A2A receptor agonist that causes peripheral vasodilation to increase blood flow, used as a pharmacologic stress agent for cardiac imaging. Used for Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise, Peripheral vascular insufficiency and claudication (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}